What is the price target for CUE stock?
5 analysts have analysed CUE and the average price target is 4.08 USD. This implies a price increase of 1444.28% is expected in the next year compared to the current price of 0.2642.
CUE BIOPHARMA INC (CUE) Forecast, Price Target & Analyst Ratings
NASDAQ:CUE • US22978P1066
Current stock price
0.2642 USD
+0.01 (+3.65%)
At close:
0.2504 USD
-0.01 (-5.22%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CUE BIOPHARMA INC (CUE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.10
- Revenue Estimate
- 2.525M
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.08
Upside
+ 1,444.28%
From current price of $0.26 to mean target of $4.08, Based on 5 analyst forecasts
Low
$4.04
Median
$4.08
High
$4.20
Price Target Revisions
1 Month
-20.00%
3 Months
-20.00%
Price Target Summary
5 Wall Street analysts provided a forecast for the next 12 months for CUE. The average price target is 4.08 USD. This implies a price increase of 1444.28% is expected in the next year compared to the current price of 0.2642.
The average price target has been revised downward by 20% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
CUE was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about CUE.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed CUE. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-25 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2025-04-02 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2024-08-20 | Stifel | Maintains | Buy -> Buy |
| 2024-07-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-04-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-09 | Stifel | Maintains | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-13 | Jefferies | Initiate | Buy |
| 2023-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-06-15 | Stifel | Reiterate | Buy -> Buy |
| 2023-05-15 | JMP Securities | Reiterate | Outperform -> Outperform |
| 2023-03-22 | Oppenheimer | Reiterate | Outperform |
| 2023-03-22 | Stifel | Maintains | Buy |
| 2022-11-21 | Piper Sandler | Initiate | Overweight |
| 2022-08-24 | Oppenheimer | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.10
- Revenue Estimate
- 2.525M
- Revenue Q2Q
- 60.22%
- EPS Q2Q
- 22.31%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
CUE is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.1 USD and the consensus revenue estimate is 2.52M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.25M -91.63% | 5.49M 339.20% | 9.287M 69.16% | 8.08M -13.00% | 10.1M 25.00% | 20.705M 105.00% | 54.995M 165.61% | 1.01M -98.16% | 1.01M | 1.01M | 47.773M 4,630.00% | 98.879M 106.98% | |
| EBITDA YoY % growth | -52.58M -23.86% | -51.436M 2.18% | -41.196M 19.91% | -54.322M -31.86% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -53.5M -22.40% | -51.992M 2.82% | -41.593M 20.00% | -39.188M 5.78% | -48.985M -25.00% | -44.44M 9.28% | -11.666M 73.75% | -60.499M -418.61% | -65.448M -8.18% | -70.801M -8.18% | -74.74M -5.56% | -25.654M 65.68% | |
| Operating Margin | -4,280.00% | -947.03% | -447.86% | -485.00% | -485.00% | -214.63% | -21.21% | -5,990.00% | -6,480.00% | -7,010.00% | -156.45% | -25.94% | |
| EPS YoY % growth | -1.50 -7.14% | -1.11 26.00% | -0.75 32.43% | -0.41 44.79% | -0.48 -17.07% | -0.42 12.50% | 0.24 157.14% | 1.50 520.83% | -0.46 -130.87% | -0.47 -2.17% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.10 22.31% | -0.11 34.65% | -0.12 -34.67% | -0.12 -73.14% | -0.13 -30.00% |
| Revenue Q2Q % growth | 2.525M 60.22% | 2.525M 499.76% | 2.525M -14.52% | 2.525M 17.50% | 2.525M |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.403M -8.04% | -11.11M 9.67% | -11.918M -38.02% | -12.625M -67.35% | -13.433M -29.13% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.78%
EPS Next 5 Year
31.99%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
29.64%
Revenue Next 5 Year
-36.13%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CUE BIOPHARMA INC / CUE Forecast FAQ
Can you provide the upcoming earnings date for CUE BIOPHARMA INC?
CUE BIOPHARMA INC (CUE) will report earnings on 2026-05-06.
What are the consensus estimates for CUE stock next earnings?
The consensus EPS estimate for the next earnings of CUE BIOPHARMA INC (CUE) is -0.1 USD and the consensus revenue estimate is 2.52M USD.
What is the number of analysts for CUE stock?
The number of analysts covering CUE BIOPHARMA INC (CUE) is 5.